Oncology Venture (OV) continues to make progress developing its oncology assets and the drug response predictor (DRP) companion diagnostic. The company has licensed six assets to date with prior clinical experience, with the hope of identifying patients with the DRP who will have an enhanced response. The most clinically advanced candidate is LiPlaCis (liposomal cisplatin). We are taking this opportunity to provide a comprehensive clinical outlook of the company.Den vollständigen Artikel lesen ...